Quratis: Q1 2026 Sales KRW 9.5M, Operating Loss KRW 2.45B, Decides Capital Reduction

Board resolution on April 14, 2026: Capital reduction (9:1 share consolidation) subject to shareholder meeting on June 1, new shares listed on July 22
Q1 2026 results: Sales KRW 9.5M, operating loss KRW 2.45B, net loss KRW 3.86B
End of period: Cash & equivalents KRW 14.42B, long-term borrowings KRW 9.43B (all current)
Accumulated deficit KRW 243.52B
Removed from 'investment caution' list on May 4, 2026 (corporate distress resolved)
Completed construction of long-acting injectable manufacturing facility with major shareholder Inventage Lab (KRW 6.89B)
Quarterly R&D expense KRW 510M; no dividend or share buyback